Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. - Wikidata - awgldk - TriplyDB

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

http://www.wikidata.org/entity/Q34116267

about

Oncolytic viruses as therapeutic cancer vaccines Thunder and lightning: immunotherapy and oncolytic viruses collide Oncolytic viruses as immunotherapy: progress and remaining challenges Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma Going viral: a review of replication-selective oncolytic adenoviruses State-of-the-art human gene therapy: part I. Gene delivery technologies Oncolytic virotherapy for human malignant mesothelioma: recent advances Adenovirus vectors for gene therapy, vaccination and cancer gene therapy Role of microRNAs in hepatocellular carcinoma: a clinical perspective Emerging role of Natural killer cells in oncolytic virotherapy Virotherapy: cancer gene therapy at last?Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives Recent advances in genetic modification of adenovirus vectors for cancer treatment Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Oncolytic immunotherapy: where are we clinically?Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials Synthetic biology for therapeutic applications.Immunotherapy for head and neck cancer: advances and deficiencies.Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Perinatal gene transfer to the liver.Increasing the efficacy of oncolytic adenovirus vectors Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Oncolytic virotherapy for ovarian cancer.Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Intrastrand triplex DNA repeats in bacteria: a source of genomic instability.Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.

P2860

Q21245758-78A66AE3-857D-420F-80C5-AD56C492925C Q24597894-52E0B373-E033-4372-B379-67A34CCD49B6 Q26745942-E29A8703-2021-421F-869A-84AA54B8309D Q26772315-47BE2292-3B21-4B48-BB92-5343FFE6CD44 Q26797520-329D641B-5EEE-4574-B2AD-57757D8DF35C Q26825575-BBBA1C5D-0501-469C-9689-EFCFA91F10B3 Q26826590-479BAE97-31A1-40D1-A0A6-20A8954E34E7 Q27001601-516DE538-F49B-4786-B68B-666FB801D2B4 Q27014034-1464A7BB-E462-4FC3-9F5A-C0DDBD85482C Q27025330-76237A60-37B2-4AAC-B275-B8CEC32430CF Q28066228-286E3D4A-8A5D-4DE4-8EF7-CD70C0F50F37 Q30899557-C88D6246-0E61-4333-956A-060A56961A21 Q33551626-81504A0D-4504-4FB8-B465-4DF10530EE18 Q33679505-515C23EA-F6D6-4154-BC04-C8311D6F7E8C Q33738828-92EB2332-0872-4443-86DB-A75B6E864A90 Q33904378-C59AFB25-605C-45AF-864F-86FFA2C998F0 Q34183436-0BFC497F-7857-4257-9068-2A95CF025DAD Q34405325-B6F8C6FF-2FA6-4053-AF72-63EA1A796095 Q34426949-E21BBC8B-380C-425C-87FD-B440D22C4F1F Q34432804-D228320D-6811-4CCB-9FCB-47AC544B176B Q35057524-8CBAAEA7-0B23-4622-A9E1-923A0DAC5AD3 Q35072040-E69E83D9-070B-4A5E-B6F8-53823C570262 Q35087653-E6211138-9477-4B52-9E23-384169B07ABD Q35110264-4A28986B-3FFE-44B9-8082-3496337B4577 Q35176800-A0479F7B-BEA6-489B-AF19-660789AC50E2 Q35238258-9B430F3C-7F24-4CA2-8FDF-C870FE9B19A0 Q35238390-8F49D71E-65C8-46EB-83D3-BF1A423E5F97 Q35261325-8ABA2725-90D5-428F-849E-0DCD6A46233C Q35285768-C826E27A-D5CC-4038-91E7-14044413DBC6 Q35506253-18AA4D6D-4F68-4CD5-9AFF-0D893AAE5459 Q35594838-EA66EBD1-BEFD-4D4F-B0AC-ECFF651880C3 Q35597082-A448F6BB-B865-42BD-ADED-C0E90E738D54 Q35653264-BBCBF3C0-6D62-4751-B093-E002C3404713 Q35665175-E6A5A759-5B84-44CA-BBFB-9054D89E33C1 Q35673240-3F568DF8-3402-41CA-B21E-C555E8D75E21 Q35840314-D928A4E3-B0E8-4336-AD94-90DDF8BB7CBF Q35855798-27E61440-42BD-449E-8792-CB1BC4A31D42 Q36220624-E2A3DC19-BE51-4E9A-9B7D-8D4328147001 Q36337642-71C456D7-E4F2-4D08-A26C-3499B1A92706 Q36664229-F93FB393-492D-47E6-B1BD-D6D27C32127E

P2860

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

http://www.wikidata.org/entity/Q34116267

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@ast

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@en

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@nl

type

label

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@ast

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@en

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@nl

prefLabel

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@ast

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@en

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@nl

P1433

Q34116267-84801524-812E-4D41-9E3E-81CB05CFB2D6

P1476

Q34116267-F7334FFB-3D05-4C8C-8152-B03FA91F4047

P2093

Q34116267-028A86E9-9DD8-4547-8148-F1BBCBEFFAF8

Q34116267-05811C76-E0AB-4011-92A5-DB118082DEDC

Q34116267-0F36B11E-347D-432B-A37A-BD0E6BE1240C

Q34116267-14D5EFDC-F57E-46A6-874F-95231C9EFB32

Q34116267-3521DD5B-983A-4435-A559-3951E345C882

Q34116267-3C69A9A0-97BA-4FF7-8928-8E66AD83BAA2

Q34116267-45A61E86-1B4E-4842-A716-0A8E728A2097

Q34116267-4AC40BD2-D638-4A34-8B89-318C015A80C5

Q34116267-60F9A58D-B097-4471-AFD5-2B8261FCE0F2

Q34116267-737EAB05-5A30-46AD-818E-5DE14382732B

P304

Q34116267-8F07A02A-011E-4EB6-A161-6FA5126413CC

P31

Q34116267-CDAB7795-FAD2-471B-836D-24E8F0C39AD7

P356

Q34116267-4E3B4A40-B93F-4E34-B802-64332CD00541

P407

Q34116267-B6EFE7CE-9851-4F62-AE81-05D7C4EF80C1

P433

Q34116267-075FF7C9-6EC7-40C9-97CD-C054B0B700CF

P478

Q34116267-7FCA93E9-FBC1-4736-9E74-F4FC52009E09

P50

Q34116267-1FA90B2D-1BA5-49C6-AF0E-F7C1C90BB410

Q34116267-2D1D8FDA-9BD7-4D99-BD45-305F33F58D75

Q34116267-4F4A0212-EBF6-4A8F-B647-8682BCA2929A

Q34116267-7D2EC1EE-4E56-4857-B5BB-79E30968437B

Q34116267-B31C653B-314D-4DF1-A4FF-BD15EE8DF82C

Q34116267-C9B5C398-7551-47E6-8CE4-25D886645C36

P577

Q34116267-2C9B4523-39EC-494C-B78F-390917CAD5EB

P698

Q34116267-3835D1AB-ACD3-489A-81C8-38439A792557

P921

Q34116267-24F485D9-4E78-457A-8170-E2250DFC8283

Q34116267-4C776784-CC91-481C-BCD3-FAFE7B9518D6

Q34116267-EE3BEBDD-53C3-48D6-9527-761D2F7AF2AE

P356

0008-5472.CAN-09-3567

P1433

Cancer Research

P1476

Oncolytic adenovirus coding fo ...... l immunity in cancer patients.

@en

P2093

Aila Karioja-Kallio

http://www.w3.org/2001/XMLSchema#string

Andreas Helminen

http://www.w3.org/2001/XMLSchema#string

Anne Räisänen-Sokolowski

http://www.w3.org/2001/XMLSchema#string

Ari Ristimäki

http://www.w3.org/2001/XMLSchema#string

Eerika Karli

http://www.w3.org/2001/XMLSchema#string

Elina Haavisto

http://www.w3.org/2001/XMLSchema#string

Kilian Guse

http://www.w3.org/2001/XMLSchema#string

Laura Ahtiainen

http://www.w3.org/2001/XMLSchema#string

Leena Laasonen

http://www.w3.org/2001/XMLSchema#string

Lotta Kangasniemi

http://www.w3.org/2001/XMLSchema#string

P304

4297-4309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-3567

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Akseli Hemminki

Sophie Escutenaire

P577

2010-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20484030

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus